Fecal calprotectin testing can identify ineffective colorectal cancer surveillance procedures in patients with longstanding colitis

Inflammatory Bowel Diseases

Volumn 20, Issue 6, 2014, Pages 1079-1084

  Mooiweer, Erik ^a   Fidder, Herma H ^a   Siersema, Peter D ^a   Laheij, Robert J F ^a   Oldenburg, Bas ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Calprotectin; Colorectal cancer; Inflammation; Inflammatory bowel disease; Surveillance

Indexed keywords

CALGRANULIN;

ADULT; AGED; ARTICLE; COLITIS; COLONOSCOPY; COLORECTAL CANCER; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ELISA KIT; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS; CHEMISTRY; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; FECES; HEALTH SURVEY; MIDDLE AGED; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; YOUNG ADULT;

ADULT; AGED; COLITIS, ULCERATIVE; COLONOSCOPY; COLORECTAL NEOPLASMS; CROHN DISEASE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; ROC CURVE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84902205227     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000054     Document Type: Article

References (24)

1. Herrinton LJ, Liu L, Levin T.R., et al Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012; 143: 382-389.
2. Lutgens MW, van Oijen MG, van der Heijden GJ, et al. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013; 19: 789-799.
3. Farraye FA, Odze RD, Eaden J, et al AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010; 138: 738-745.
4. Cairns SR, Scholefield JH, Steele R.J., et al Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010; 59: 666-689.
5. Annese V, Daperno M, Rutter M.D., et al European evidence concensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013; 7: 982-1018.
6. Kiesslich R, Fritsch J, Holtmann M., et al Methylene blue-aided chro-moendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124: 880-888. (Pubitemid 36389789)
7. Rutter MD, Saunders BP, Schofield G, et al Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004; 53: 256-260. (Pubitemid 38125515)
8. Marion JF, Waye JD, Present D.H., et al Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dys-plasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol. 2008; 103: 2342-2349.
9. Riddell RH, Goldman H, Ransohoff D.F., et al Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol. 1983; 14: 931-968.
10. van Schaik F.D., Ten Kate FJ, Offerhaus GJ, et al Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis. 2011; 17: 1108-1116.
11. Odze RD, Goldblum J, Noffsinger A., et al Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002; 15: 379-386. (Pubitemid 34326945)
12. Cellier C, Sahmoud T, Froguel E., et al Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileo-colonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut. 1994; 35: 231-235. (Pubitemid 24092870)
13. Osada T, Ohkusa T, Okayasu I., et al Correlations among total colono-scopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J Gastroenterol Hepatol. 2008; 23(SUPPL. 2):S262-S267.
14. Baars JE, Nuij VJ, Oldenburg B, et al Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis. 2012; 18: 1634-1640.
15. D'Haens G., Ferrante M, Vermeire S., et al Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2218-2224.
16. Schoepfer AM, Beglinger C, Straumann A., et al Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19: 332-341.
17. Schoepfer AM, Beglinger C, Straumann A., et al Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010; 105: 162-169.
18. Hanley JA, McNeil BJ A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148: 839-843. (Pubitemid 13033817)
19. Higgins PD, Schwartz M, Mapili J., et al Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005; 54: 782-788. (Pubitemid 40732094)
20. Rosenberg L, Nanda KS, Zenlea T, et al Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clin Gas-troenterol Hepatol. 2013; 11: 991-996.
21. Baars JE, Vogelaar L, Wolfhagen F.H., et al A short course of corticosteroids prior to surveillance colonoscopy to decrease mucosal inflammation in inflammatory bowel disease patients: results from a randomized controlled trial. J Crohns Colitis. 2010; 4: 661-668.
22. Rutter M, Saunders B, Wilkinson K., et al Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterol-ogy. 2004; 126: 451-459. (Pubitemid 38182302)
23. Gupta RB, Harpaz N, Itzkowitz S., et al Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105; quiz 1340-1341. (Pubitemid 47494461)
24. Ullman TA, Itzkowitz SH Intestinal inflammation and cancer. Gastroen-terology. 2011; 140: 1807-1816.